Adempas

Kraj: Nowa Zelandia

Język: angielski

Źródło: Medsafe (Medicines Safety Authority)

Składnik aktywny:

Riociguat 1mg

Dostępny od:

Bayer New Zealand Limited

INN (International Nazwa):

Riociguat 1 mg

Dawkowanie:

1 mg

Forma farmaceutyczna:

Film coated tablet

Skład:

Active: Riociguat 1mg Excipient: Crospovidone Hyprolose Hypromellose   Iron oxide yellow Lactose monohydrate Magnesium stearate Microcrystalline cellulose Propylene glycol Purified water Sodium laurilsulfate Titanium dioxide

Typ recepty:

Prescription

Wyprodukowano przez:

Bayer AG

Wskazania:

Pulmonary arterial hypertension Adempas, as monotherapy or in combination with approved PAH treatments (endothelin receptor agonists or inhaled or subcutaneous prostanoids ), is indicated for the treatment of: - idiopathic pulmonary arterial hypertension - heritable pulmonary arterial hypertension - pulmonary arterial hypertension associated with connective tissue diseases - pulmonary arterial hypertension associated with congenital heart disease in adult patients with WHO functional Class II, III or IV symptoms.

Podsumowanie produktu:

Package - Contents - Shelf Life: Blister pack, PP/Al - 42 tablets - 36 months from date of manufacture stored at or below 30°C - Blister pack, PP/Al - 84 tablets - 36 months from date of manufacture stored at or below 30°C

Data autoryzacji:

2014-06-25